ADHD medication and your heart: what most people miss

Summary

Seven things to know about ADHD medication and your heart

What it does

Every ADHD medicine except guanfacine raises heart rate by a few beats a minute and blood pressure by 2 to 3 mmHg on average. Serious heart problems are rare, but years of use are linked with a higher chance of high blood pressure.

Before you start

A proper check is mostly questions and an examination: your health, your family’s health, pulse and blood pressure measured with the right cuff and someone listening to your heart. Most people don’t need an ECG.

Red flags

Some answers mean seeing a heart specialist before you start, such as fainting during exercise or with a sudden fright or noise, a sudden death under 40 in your close family or a heart murmur.

Often missed

The usual gaps are faints that get explained away, vague questions about family history, no examination, readings taken after the first dose and everyday stimulants such as coffee, nicotine and decongestants.

Dizzy or hypermobile?

Ask for a lying and standing blood pressure and pulse check before you start. It takes about ten minutes and can change which medicine suits you.

Once you’re on it

Your pulse and blood pressure should be checked after every dose change and at least every six months, for as long as you take the medicine.

When to get help

Get advice the same day if you faint or nearly faint, or if palpitations come with dizziness, breathlessness or chest discomfort. Call 999 for severe chest pain or a collapse.

Why this matters

ADHD medication is safe for most hearts, and a proper check finds the exceptions

For most people, ADHD medication is safe for the heart. It nudges heart rate and blood pressure up a little, and the chance of anything serious happening is very small. But that small risk isn’t spread evenly. It sits with a few people who have a heart problem nobody has spotted yet, and the way to find them is a careful history and examination before the first dose, not a blanket test for everyone.

I’m asked about this most weeks. Sometimes it’s someone who has read a frightening headline and is wondering whether to start at all. Sometimes it’s someone who has been sent a blood pressure monitor, asked to take their own readings and left to get on with it. Both situations miss the real question. It isn’t whether ADHD medication is dangerous. It’s whether the person prescribing it has asked you the right things.

This guide explains what the medication actually does to your heart and circulation, what a good check involves under the NICE guideline for ADHD (NG87) and the handful of things that get missed most often. Whether you’re about to start treatment or you’ve been on it for years, it should help you know what to expect and what to ask.

What the medicine does

The effect on heart rate and blood pressure is small, but it adds up over years

Every ADHD medicine except guanfacine raises heart rate and blood pressure a little. That includes the stimulants, methylphenidate (Concerta XL, Xaggitin XL, Medikinet XL) and lisdexamfetamine (Elvanse), as well as the non-stimulant atomoxetine. They all work by boosting noradrenaline and dopamine in the brain, and noradrenaline is also the chemical that tells your heart to beat faster and your blood vessels to tighten.

The average change is modest. The largest analysis of the trials, published in The Lancet Psychiatry in 2025, pooled 102 studies and more than 22,000 people. It found average rises of around 2 to 3 mmHg in blood pressure and 4 to 6 beats a minute in pulse. Most people never notice it.

Averages hide the people at the far end, though. In adult trials, about 4 in 100 people on a stimulant had a resting heart rate above 90, compared with fewer than 2 in 100 on placebo. That’s why your own response needs measuring rather than assuming.

The longer view matters too. A Swedish study of 278,000 people, published in JAMA Psychiatry in 2024, found that each extra year on ADHD medication was linked with about a 4% higher risk of cardiovascular disease, reaching 23% higher after more than five years. Most of that was high blood pressure and disease of the arteries. The study was observational, so it can’t prove the medicine caused it, but it fits with a small rise in blood pressure kept up over years.

The more frightening outcomes are much less clear. A review of studies covering 3.9 million people found no clear link between ADHD medication and heart attack or stroke. In children, reported rates of sudden death on ADHD medication are similar to the rate in children generally. Where serious events do happen, they cluster in people who already had a heart condition, often one nobody knew about.

It’s also worth knowing that untreated ADHD carries its own risk. In a study of over 5 million Swedish adults, 38% of those with ADHD had at least one cardiovascular diagnosis over about 12 years, against 24% of those without. Smoking, weight, sleep and other health conditions explain some of that gap but not all of it. Starting ADHD medication has also been linked with a lower risk of dying from any cause, mainly through fewer accidents and injuries. So the choice isn’t between risk and no risk. It’s about knowing your own heart well enough to choose well.

Before you start

A proper heart check before ADHD medication is mostly questions, not tests

In the UK, the minimum standard is set by NICE in its ADHD guideline, NG87. Before you start medication, your prescriber should take a medical history (including anything that might rule out a particular medicine), check what else you take and measure your height and weight. They should also measure your pulse and blood pressure with a cuff that’s the right size for your arm, compare the readings with the normal range for your age and carry out a cardiovascular assessment.

The heart of that assessment is a set of questions. NICE says you should be referred for a cardiology opinion before starting ADHD medication if any of these apply:

For children and young people, blood pressure that’s consistently above the 95th centile for their age and height means a referral to a paediatric hypertension specialist first.

What isn’t on the list is a routine ECG for everyone. NICE, the American Academy of Pediatrics, the Canadian ADHD guideline group (CADDRA), the Australian 2022 guideline and the European ADHD guidelines group all agree on this. An ECG is the right test when your history points to a problem, or when you take another medicine that affects the heart, and it should be done before the first dose rather than after.

As a test for everybody, an ECG mostly adds delay and false alarms. When a children’s cardiology department in Dublin audited six months of referrals made before ADHD medication, more than half had no clinical reason to be referred. Of the 80 children whose results could be reviewed, 72 were normal and only one had a finding that mattered for medication. The conditions that matter most usually show themselves in the story first, which is why the questions above do more work than any machine.

The gaps

What most people miss before starting ADHD medication

When something goes wrong with ADHD medication and the heart, it’s rarely because the wrong medicine was chosen. It’s usually because a question wasn’t asked or a check was skipped. These are the gaps I see most often.

Fainting during exercise isn’t ‘just a faint’

Fainting on exertion, or in response to a fright or a sudden noise, is on NICE’s list for a reason. It can be the first sign of a heart muscle condition such as hypertrophic cardiomyopathy, or of an inherited rhythm problem such as long QT syndrome, where a shrill alarm or a sudden shock is a classic trigger. These conditions are rare, but they’re exactly the ones where a stimulant could tip the balance.

The faint often gets explained away. It was the heat, a missed meal, low blood sugar or an allergic reaction. One of those may well be the answer, but ‘most likely’ isn’t good enough when the alternative is a heart rhythm problem. NICE asks for a cardiology opinion here, not just an ECG. A collapse during exercise also deserves specialist heart assessment in its own right, whether or not ADHD medication is on the table.

A family history needs the right question

‘Any heart problems in the family?’ usually gets the answer ‘My grandad had a heart attack at 80’, which isn’t what we’re looking for. The question that matters is whether anyone in your close family died suddenly or unexpectedly before the age of 40. That includes an unexplained drowning, a death in their sleep, a collapse during sport or a young relative who needed a pacemaker or an implanted defibrillator.

If the answer is yes, that’s a reason to see an inherited cardiac conditions specialist before starting, even if you feel completely well.

Somebody should listen to your heart

A heart murmur is one of NICE’s red flags, and the only way to find one is to examine you. When one UK child mental health team audited its practice against NG87, its cardiovascular checks fell short mainly because the heart examination wasn’t being done. Measuring blood pressure isn’t the same as assessing the heart.

A baseline has to come before the first dose

A baseline is the reading taken before you start, measured properly with the right size of cuff. A cuff that’s too small reads falsely high, and readings taken after you’ve started can’t tell anyone what changed. Home blood pressure monitors are genuinely useful, especially for checking your response once you’re on treatment. But a monitor in the post isn’t a cardiovascular assessment. It can’t take a history and it can’t listen to your heart.

Everyday stimulants add up

Your heart doesn’t know which stimulant it’s responding to. Coffee, energy drinks, pre-workout powders, nicotine (including vapes and pouches) and decongestants such as pseudoephedrine all push heart rate and blood pressure the same way ADHD medication does. Cannabis can cause a fast pulse and dizziness on standing, and cocaine or street amphetamines add a far bigger load.

Your prescriber also needs a full list of your medicines. Fluoxetine and paroxetine raise atomoxetine levels in the blood. MAOI antidepressants must not be taken with stimulants or atomoxetine. Blood pressure tablets may work less well alongside a stimulant. None of this has to stop treatment, but it changes the plan.

Other conditions can speed the heart up

An overactive thyroid raises heart rate and rules out amphetamine-based medicines such as Elvanse. Anaemia and low iron cause a fast pulse and dizziness when you stand. An eating disorder or very low weight leaves the heart more vulnerable to rhythm problems, and anorexia is listed as a reason not to use methylphenidate. If your history hints at any of these, a blood test before starting makes sense.

Cold, white or painful fingers

Stimulants can narrow the small blood vessels in the fingers and toes and cause Raynaud’s phenomenon, where fingers turn white or blue in the cold and ache as they warm up. It’s listed in the UK product information for methylphenidate and carries a warning across all stimulants in the US. If you already have cold hands, it’s worth recording before you start so any change is noticed. It usually settles with a lower dose or a change of medicine.

Special cases

Dizziness, hypermobility and ADHD medication need a closer look

If you get dizzy when you stand up, faint easily or have very flexible joints, the part of your nervous system that runs your heart rate and blood pressure deserves a closer look before you choose a medicine. Doctors call it the autonomic nervous system. When it isn’t working smoothly, that’s called dysautonomia.

Hypermobility is much more common in neurodivergent people. In a UK study of 109 adults with ADHD, autism or Tourette’s, about half had generalised joint hypermobility, against about 1 in 5 in the general population. In Swedish registry data, ADHD was diagnosed five to six times as often in people with Ehlers-Danlos syndrome, with similar findings for hypermobility syndrome. People with hypermobility in turn often have a form of dysautonomia called postural tachycardia syndrome, or POTS. Among 91 people with POTS in one US study, nearly a third met the criteria for hypermobile Ehlers-Danlos syndrome.

So the link between ADHD and POTS seems to run largely through hypermobility. There isn’t yet a reliable figure for how many people with ADHD have POTS, and you’ll see bigger claims online than the evidence supports.

What POTS looks like

In POTS, your heart rate climbs by 30 beats a minute or more within 10 minutes of standing (40 or more in teenagers), without your blood pressure dropping. People describe dizziness, a pounding heart, tiredness and brain fog. It’s most often diagnosed in young women. Some of those symptoms overlap with ADHD, which is another reason to look for it rather than assume.

How the medicines interact

Stimulants raise heart rate, so they can make POTS symptoms worse. But they also tighten blood vessels, and some POTS specialists use methylphenidate for people whose symptoms haven’t responded to anything else. In one small study, 14 of the 18 people who stayed on it for six months felt markedly better. You can’t predict which way it will go for you, so it needs measuring.

Guanfacine (Intuniv) works the other way. It lowers blood pressure and heart rate, which can make dizziness and fainting worse, and NICE says the dose should be reduced or the medicine changed if that happens. Atomoxetine raises heart rate about as much as a stimulant, so it isn’t automatically the gentler choice here.

The ten-minute test that changes decisions

The check that helps is a lying and standing blood pressure and pulse, measured after you’ve been lying down and then repeatedly over several minutes after you stand. It isn’t a NICE requirement, but it’s good practice whenever there’s dizziness, fainting, hypermobility or known POTS, and before starting guanfacine. It takes about ten minutes and it can change which medicine you’re offered.

If you bruise very easily as well as being hypermobile, it’s worth your doctor considering a rare form called vascular Ehlers-Danlos syndrome. It affects the blood vessels, which matters when choosing a medicine that raises blood pressure.

Once you’re on it

Monitoring doesn’t stop once your dose is settled

NICE asks for your pulse and blood pressure to be checked before and after every dose change, then every six months. Given what the long-term studies show about blood pressure, I’d keep those six-monthly checks going for as long as you take the medicine, not just in the first year.

Your prescriber should act if your resting heart rate stays above 120, if your heart rhythm becomes irregular or if your blood pressure is clearly raised on two separate occasions. That usually means a lower dose and a review by a doctor who looks after blood pressure or the heart. For adults, home or 24-hour monitoring is the best way to confirm a raised reading.

Getting home readings right

This is where a home monitor comes into its own. Sit quietly for five minutes first, with your back supported and your arm resting at heart height. Use a cuff that fits your upper arm. Take two readings a minute apart and write both down. It helps to measure at the same times each day, once before your dose and once a few hours after, when the medicine is working hardest.

Pausing a stimulant for a week or two while things are checked carries no medical risk, although your ADHD symptoms will come back while you’re off it. Guanfacine is the exception. Stopping it suddenly can make your blood pressure rebound, so ring for advice rather than just stopping.

Questions worth asking before you start

Your questions

Frequently asked questions about ADHD medication and the heart

Summary

Eight points for prescribers on cardiovascular safety

Haemodynamics

Every noradrenergic ADHD drug raises blood pressure by about 1 to 3 mmHg and pulse by about 3 to 6 bpm on average, and stimulants raise them no more than atomoxetine does. Guanfacine lowers both.

Long-term risk

Each year of use carries about 4% higher CVD risk, driven by hypertension and arterial disease. There’s no clear signal for MI or stroke, though a small rise in arrhythmia or cardiac arrest can’t be excluded. Untreated ADHD carries its own risk.

NG87 baseline

Take a history, record current medication, measure height and weight, measure pulse and blood pressure with an appropriately sized cuff and do a cardiovascular assessment, all before the first dose. A murmur is a referral trigger, so examine the heart.

Cardiology referral

Any 1.7.5 feature needs a cardiology opinion, which an ECG alone doesn’t satisfy. Exertional loss of consciousness in over-16s also meets the CG109 standard for specialist assessment within 24 hours.

Routine ECG

No major guideline supports it. In a Dublin audit of pre-medication referrals, 1 of the 80 reviewed had a finding that mattered, and that referral met NICE criteria anyway.

Often missed

The common gaps are exertional and startle syncope explained away, loose family histories, no auscultation, post-dose readings used as a baseline and unrecognised pressor load from interactions and substances.

Hypermobility and POTS

Hypermobility is over-represented in ADHD and brings dysautonomia with it. Do an active stand before choosing a drug, and especially before an alpha-2 agonist.

Monitoring

Check pulse and blood pressure before and after each dose change, then six-monthly for the life of treatment. Act on a sustained resting rate above 120, arrhythmia or a significant rise in blood pressure on two occasions.

For prescribers, GPs and pharmacists

Cardiovascular assessment for ADHD medication: what NG87 requires and where practice falls short

ADHD medication is cardiovascularly safe for most patients, and the evidence supports a history-led screen rather than routine investigation. The risk that matters sits with people who have undiagnosed structural heart disease, a channelopathy or exertional syncope, which is why NICE NG87 builds its referral criteria around history and examination. In audit, the weak point in UK practice is usually the examination and the history, not too few ECGs.

Haemodynamics

Average effects are small and similar across classes, but the tail is real

The most complete synthesis is Farhat and colleagues’ network meta-analysis in The Lancet Psychiatry (2025): 102 randomised trials, 13,315 children and adolescents and 9,387 adults, with a median follow-up of 7 weeks. Amphetamines, atomoxetine, lisdexamfetamine, methylphenidate and viloxazine all raised blood pressure and pulse. Stimulants were not associated with larger rises than atomoxetine or viloxazine. Guanfacine lowered all three measures.

Ranges span the agents that produced significant changes (amphetamines, atomoxetine, lisdexamfetamine, methylphenidate, viloxazine). Short-term trials, median 7 weeks. CINeMA confidence was mostly moderate to high in children and very low in adults. Source: Farhat et al., Lancet Psychiatry 2025.

The authors’ conclusion is the practical one: monitor blood pressure and pulse with any ADHD drug, not stimulants only.

Averages conceal outliers. Mick and colleagues’ adult meta-analysis found that stimulants raised resting heart rate by 5.7 bpm and systolic pressure by 2.0 mmHg, with a resting heart rate above 90 bpm in 4.2% on stimulants against 1.7% on placebo (OR 2.75). The European guidelines group reported atomoxetine trial data with systolic pressure above the 95th centile in 6.8% against 3% on placebo, and rare individual heart rate rises of up to 50 bpm.

Methylphenidate blocks dopamine and noradrenaline reuptake. Amphetamines block reuptake and also release monoamines. Atomoxetine inhibits noradrenaline reuptake. All of them raise peripheral sympathetic tone. Guanfacine and clonidine reduce sympathetic outflow, so their risks are bradycardia, orthostatic hypotension, syncope and rebound hypertension on abrupt withdrawal.

Long-term risk

The long-term signal is hypertension and arterial disease

Zhang and colleagues’ Swedish nested case-control study (JAMA Psychiatry, 2024; 278,027 people aged 6 to 64) found that each additional year of ADHD medication was associated with a 4% higher risk of cardiovascular disease (AOR 1.04, 95% CI 1.03 to 1.05), with a steeper rise over the first three years (AOR 1.08). Use for more than five years carried a 23% higher risk than non-use (AOR 1.23). The excess was concentrated in hypertension (AOR 1.72 for 3 to 5 years and 1.80 for more than 5 years) and arterial disease (AOR 1.65 for 3 to 5 years). The authors concluded that cardiovascular signs should be monitored regularly and consistently throughout treatment.

The same group’s earlier meta-analysis (JAMA Network Open, 2022; 19 observational studies, 3.9 million participants) found no statistically significant association with cardiovascular disease overall. Confidence intervals were wide. A modest increase in cardiac arrest or tachyarrhythmia could not be excluded (RR 1.60, 95% CI 0.94 to 2.72), and estimates for women (RR 1.88, 0.43 to 8.24) and older adults (RR 1.59, 0.62 to 4.05) were too imprecise to reassure. There was no signal for myocardial infarction (RR 1.06) or cerebrovascular disease (RR 0.91).

For sudden death, the European guidelines group estimated reported rates of 0.2 to 0.5 per 100,000 patient-years in children on ADHD medication, against background paediatric rates with a median of 1.2 to 1.3 per 100,000 per year. They judged the risk similar to that of children in general, while accepting that a very rare excess cannot be completely excluded.

Untreated ADHD is itself a cardiovascular risk factor. In 5,389,519 Swedish adults (Li et al., World Psychiatry 2022), 38.05% of those with ADHD against 23.57% of those without had at least one cardiovascular diagnosis over a mean of 11.8 years. The hazard ratio fell from 2.05 to 1.84 after adjustment for education, diabetes, obesity, dyslipidaemia, sleep problems and heavy smoking, then to 1.65 after adjustment for psychiatric comorbidity. In a target trial emulation (Li et al., JAMA 2024), starting ADHD medication was associated with lower two-year all-cause mortality (HR 0.79, 95% CI 0.70 to 0.88), driven by unnatural causes. Natural-cause mortality did not differ significantly (HR 0.86, 0.71 to 1.05).

NICE NG87

What NG87 requires before the first dose

Recommendation 1.7.4 sets out the baseline. Before starting medication, the physical health review should include a medical history that takes account of possible contraindications, current medication, height and weight measured against the normal range, baseline pulse and blood pressure measured with an appropriately sized cuff and compared with the normal range for age and a cardiovascular assessment. An ECG is not needed before starting stimulants, atomoxetine or guanfacine unless a 1.7.5 feature is present or a co-existing condition is being treated with a medicine that may pose an increased cardiac risk.

Recommendation 1.7.5 asks for a cardiology opinion before starting ADHD medication if any of the following apply.

Recommendation 1.7.6 adds referral to a paediatric hypertension specialist when blood pressure is consistently above the 95th centile for age and height. Recommendation 1.7.28 asks for slower titration and more frequent monitoring with physical health conditions such as cardiac disease. The committee was open that it drew these referral criteria from experience, so they are consensus recommendations rather than outcome-derived thresholds.

Two adjacent standards are easy to forget. NICE’s transient loss of consciousness guideline for people over 16 (CG109) asks for referral within 24 hours for specialist cardiovascular assessment when loss of consciousness occurs during exertion, whatever the ADHD plan. A family history of sudden death under 40 justifies referral to an inherited cardiac conditions service on the history alone.

Product information adds its own layer. The Concerta XL SPC contraindicates methylphenidate in pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies, unless specialist cardiac advice has been obtained. It also contraindicates use in cerebrovascular disorders and in anorexia nervosa. Its statement that adults new to Concerta XL need cardiologist advice ‘if required by national practice’ is answered in the UK by NG87, which does not require it routinely.

The Elvanse SPC contraindicates lisdexamfetamine in symptomatic cardiovascular disease, moderate to severe hypertension, advanced arteriosclerosis, hyperthyroidism, glaucoma, agitated states and MAOI use within 14 days. Atomoxetine is contraindicated in severe cardiovascular and cerebrovascular disorders and phaeochromocytoma. Its QT warnings matter most in CYP2D6 poor metabolisers and with CYP2D6 inhibitors.

Routine ECG

No major guideline supports a routine pre-treatment ECG

NICE, the American Academy of Pediatrics, CADDRA, the Australian 2022 ADHD guideline and the European guidelines group all reserve ECG and cardiology input for indications found on history and examination. The European group found no evidence of incremental benefit from routine ECG and cited economic evaluations showing it is not cost-effective for preventing sudden death. The American Heart Association’s 2008 suggestion that an ECG was reasonable in children was later clarified, jointly with the AAP, as not mandatory.

The cost of over-referral is measurable. A prospective six-month audit of 91 pre-medication referrals to the cardiology department at Crumlin, Dublin (Pentony et al., Cardiology in the Young 2024) found that 58.2% had no clinical indication and only 28.5% met NICE criteria. Of the 80 with outcomes available, 72 (90%) were normal. One (1%) had a clinically significant abnormality, and that referral had met NICE criteria. Routine screening contributed to delays in starting treatment.

QTc is not the main concern. The European group found that average QTc was not significantly changed by methylphenidate, mixed amphetamine salts or atomoxetine, and saw no indication to monitor QTc routinely with stimulants. The hazard is unmasking an existing substrate such as long QT syndrome, Brugada syndrome, Wolff-Parkinson-White, hypertrophic or arrhythmogenic cardiomyopathy or congenital heart disease. History is the screen for those.

Where assessments fall short

What gets missed in practice

Exertional and startle syncope

Syncope on exertion raises hypertrophic cardiomyopathy, catecholaminergic polymorphic ventricular tachycardia, long QT type 1 and anomalous coronary origin. Syncope triggered by fright or a sudden noise is a classic long QT type 2 presentation. The common error is to attribute the event to a benign cause, such as heat, hypoglycaemia or anaphylaxis, on probability alone. In food-dependent exercise-induced anaphylaxis, collapse during exercise may be anaphylactic hypotension or arrhythmic syncope, and the two can’t be separated without assessment. Treat exertional collapse as cardiac until proven otherwise, and remember that NG87 asks for a cardiology opinion, which an ECG alone does not satisfy.

A family history taken too loosely

Ask specifically about sudden or unexplained death under 40, death during exercise or in sleep, unexplained drowning, cardiomyopathy or channelopathy in relatives and pacemakers or implantable defibrillators in young family members. ‘Any heart problems in the family?’ mostly turns up late-life coronary disease.

No cardiac examination

A murmur is a 1.7.5 trigger and can only be found by auscultation. A BJPsych Open audit of NG87 compliance in a Manchester CAMHS community team (2023) found that cardiovascular risk assessments fell short mainly because cardiac examination was missing, which directly affects murmur-triggered referral. Examination should also look for signs of heart failure and check peripheral pulses.

A baseline that isn’t a baseline

Baseline pulse and blood pressure need to be measured before the first dose, with a cuff sized to the arm, and compared with the normal range for age. A home monitor is a useful supplement, and NICE NG136 uses home and ambulatory readings to confirm hypertension. But it isn’t a history or an examination, and readings taken after starting cannot serve as a baseline.

Pressor load and interactions

Conditions that change the picture

Hyperthyroidism is a contraindication for amphetamines and a precaution for methylphenidate, so check thyroid function if there are signs. Anaemia and iron deficiency cause tachycardia and orthostatic intolerance, and a full blood count and ferritin are reasonable where symptoms suggest them. Eating disorders and low BMI bring bradycardia, electrolyte disturbance and QT prolongation. In established cardiovascular disease or in older adults, involve cardiology and titrate slowly. With hypertension, diabetes or metabolic syndrome, treat blood pressure to target first. Adult-range hypertension is itself a 1.7.5 referral criterion.

Peripheral vasculopathy

The UK Concerta XL SPC lists peripheral coldness and Raynaud’s phenomenon among vascular adverse reactions, and US labels carry a class warning for peripheral vasculopathy across stimulants, with digital ulceration reported in severe cases. Record baseline digital symptoms and ask about them at each review. Symptoms generally improve with dose reduction or withdrawal.

Hypermobility and dysautonomia

Hypermobility is the link between ADHD and autonomic symptoms

The association between neurodivergence and hypermobility is robust. Csecs and colleagues (Frontiers in Psychiatry, 2022) found generalised joint hypermobility in 51% of 109 neurodivergent adults, against 20% in the general population (OR 4.51, 95% CI 2.17 to 9.37). The number of hypermobile joints mediated the relationship between neurodivergence and symptoms of both dysautonomia and pain. In a Swedish nationwide cohort (Cederlöf et al., BMC Psychiatry 2016), ADHD was diagnosed more often in Ehlers-Danlos syndrome (RR 5.6, 95% CI 4.2 to 7.4), with similar findings in hypermobility syndrome.

Dysautonomia is common in hypermobility. Of 91 POTS patients, 31% met the 2017 criteria for hypermobile EDS and a further 24% had generalised joint hypermobility (Miller et al., Autonomic Neuroscience 2020). There is no robust estimate of POTS prevalence in ADHD itself. The defensible statement is that dysautonomia is common in hypermobility and hypermobility is over-represented in ADHD. Estimates of mast cell activation syndrome in POTS vary enormously with the criteria used, and the case for a specific hEDS, POTS and MCAS triad is weak.

Active stand

Measure supine blood pressure and heart rate, then repeat over 10 minutes of standing. A sustained heart rate rise of 30 bpm or more in adults (40 bpm or more at age 12 to 19), without orthostatic hypotension and with chronic orthostatic symptoms, suggests POTS. It isn’t an NG87 requirement, but it’s good practice with orthostatic dizziness, syncope or presyncope, known POTS or hEDS, and before guanfacine or clonidine.

Choosing and titrating

Stimulants raise standing heart rate and may limit tolerability in POTS, yet they also increase vascular tone and are used off-label in refractory POTS. In Kanjwal and colleagues’ retrospective series (American Journal of Therapeutics, 2012), 14 of 18 patients who completed six months on methylphenidate reported marked improvement in fatigue and presyncope, and 9 of 12 with recurrent syncope had none at follow-up. The evidence is low quality, but it argues for measuring rather than assuming. Atomoxetine raises heart rate to a similar degree. Alpha-2 agonists carry the opposite risk, and NG87 1.8.12 advises reducing the dose or switching if a patient on guanfacine has sustained orthostatic hypotension or fainting.

Easy bruising with hypermobility should prompt consideration of vascular EDS, given arterial fragility and the relevance of pressor agents. Thin translucent skin and a family history of arterial or organ rupture strengthen the case for a genetics referral.

Monitoring

Monitor for the life of treatment

Given the long-term hypertension signal, six-monthly checks should continue for as long as treatment does, not stop after titration. Ask about cold, painful or colour-changing digits at every review. In adults, the NG136 thresholds (clinic 140/90 or above, confirmed by an ambulatory or home average of 135/85 or above) give a practical definition of a clinically significant rise.

Checklist

A pre-prescribing checklist mapped to sources

Women

Hormones and sex differences: good practice, thin evidence

Evidence is growing that ADHD symptoms fluctuate with oestradiol and worsen in the late luteal phase, and a small case series suggests some women benefit from a premenstrual stimulant dose increase. There are no randomised trials in perimenopausal women and no UK guideline mandates a hormonal history, so it stands as good practice. The cardiovascular points specific to women are practical ones. POTS is most common in young women, blood pressure needs closer surveillance in pregnancy and cardiovascular risk rises after menopause. The 2022 meta-analysis also could not exclude a meaningful signal in female patients.

Anaphylaxis

Never withhold adrenaline because of a stimulant

No study or guideline recommends withholding or adjusting adrenaline in anaphylaxis because a patient takes a stimulant. Interaction databases flag additive sympathomimetic effects, but, as with beta-blockers, adrenaline must never be withheld. Methylphenidate itself rarely causes hypersensitivity reactions.